Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation

Multi‐targeted agents represent the next generation of targeted therapies for solid tumors, and patients with acquired resistance to EGFR‐tyrosine kinase inhibitors (TKIs) may also benefit from their combination with TKI therapy. Third‐generation targeted drugs, such as osimertinib, are very expensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Pinghui, Cao, Jinlin, Lv, Xiayi, Wang, Luming, Lv, Wang, Hu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928351/
https://www.ncbi.nlm.nih.gov/pubmed/29575765
http://dx.doi.org/10.1111/1759-7714.12624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928351/
https://www.ncbi.nlm.nih.gov/pubmed/29575765
http://dx.doi.org/10.1111/1759-7714.12624

Ejemplares similares